Becton, Dickinson and Company (BDX) reported fiscal Q1 2026 revenue of $5.3 billion, representing a 0.4% increase, with the 'New BDX' (excluding the divested Life Sciences business) growing 2.5%. Adjusted EPS of $2.91 declined 15.2% year-over-year but exceeded expectations, driven by an adjusted gross margin of 53.4% and strong operational execution despite a 170-basis point headwind from tariffs. The company successfully closed its Reverse Morris Trust transaction with Waters ahead of schedule, receiving a $4 billion cash distribution which will be used for $2 billion in share repurchases via ASR and $2 billion in debt reduction. Management guided for fiscal 2026 revenue growth in the low single digits and adjusted EPS of $12.35 to $12.65, reflecting confidence in their 'Compete, Innovate, Deliver' strategy and the resilience of their high-growth platforms like GLP-1 drug delivery and pharmacy automation.
| Metric | Value | Change |
|---|---|---|
| Total Revenue | $5.3 Billion | +0.4% |
| New BDX Revenue Growth | N/A | +2.5% |
| Adjusted EPS | $2.91 | -15.2% |
| Adjusted Gross Margin | 53.4% | -140 bps |
| Adjusted Operating Margin | 21.2% | -240 bps |
| Free Cash Flow | $548 Million | N/A |
| Net Leverage | 2.9x | N/A |
Management emphasized the completion of the Reverse Morris Trust transaction with Waters, marking the final step in BDX's transformation into a 'pure-play medtech company.' This strategic pivot allows BDX to focus resources on higher-growth areas like Medical Essentials, Connected Care, and Interventional segments. The transaction closed nearly two months ahead of schedule, unlocking significant shareholder value through a $4 billion cash distribution. This move simplifies the portfolio and concentrates investments on areas with billion-dollar-plus potential, aligning with the three key healthcare trends identified by the CEO: smart connected devices, shift to outpatient care, and chronic disease management.
The company is aggressively deploying capital to enhance shareholder returns, utilizing $2 billion of the Waters proceeds for an Accelerated Share Repurchase (ASR) and another $2 billion for debt paydown. This action signals a shift in capital allocation strategy towards prioritizing share repurchases and debt reduction while maintaining a reliable dividend. By reducing net leverage from 2.9 times towards a 2.5 times target, BDX is improving its financial flexibility. This disciplined capital deployment underscores management's confidence in the free cash flow generation capabilities of the 'New BDX' entity.
BDX's 'Compete' strategic priority is yielding tangible results, evidenced by broad-based market share gains across key product lines. Alaris pumps delivered their strongest quarter of competitive wins since the relaunch, gaining approximately 100 basis points of category share. The Pyxis Pro launch saw 85% of initial orders coming from competitive conversions. Additionally, the Pharma Systems segment secured over 80 novel and biosimilar GLP-1 molecules. These wins demonstrate the effectiveness of recent sales force expansions and commercial initiatives, positioning the company for sustained revenue growth as these wins convert to recurring revenue streams.
Innovation remains a core pillar, with management reallocating $50 million from central R&D to business units to fund high-growth platforms. The company is entering new markets, such as biosurgery with Avatene Flowable and wound irrigation with SurgiFor, expanding their served market by over $550 million. Furthermore, the application of 'BD Excellence' methodologies to R&D has accelerated product launch timelines by six to twelve months. This focus on productivity and innovation is crucial for offsetting headwinds and driving long-term margin expansion.
Operational excellence, branded as 'BD Excellence,' continues to drive margin resilience despite significant tariff headwinds. The company achieved 8% productivity improvements in the quarter and has successfully consolidated its manufacturing network by nearly half, reducing sites from over 90 to under 50. This simplification lowers costs and improves resiliency. These efficiency gains, combined with a favorable mix shift towards higher-margin products, are critical factors supporting the guidance for a 25% adjusted operating margin for the full fiscal year.
Adjusted EPS declined by 15.2% year-over-year to $2.91, primarily driven by a 170-basis point impact from tariffs. While operational execution was strong, the magnitude of the tariff impact highlights a persistent external pressure on profitability. Management noted that tariffs will continue to be a headwind throughout fiscal 2026, impacting the adjusted operating margin guidance by approximately 370 basis points. Investors need to monitor if pricing actions and productivity can fully offset these costs over time.
The Alaris segment continues to face significant headwinds due to the 'tough comparison' to the prior year and the tail end of remediation efforts. While management celebrated competitive wins and share gains, the revenue performance was still down, and the headwind is expected to step up to 200 basis points in fiscal 2027. This indicates that the financial benefits of the recent market share gains will be lagged and that the segment will remain a drag on growth for the foreseeable future before a potential recovery.
Management maintained a 'prudent' full-year guidance despite Q1 results exceeding expectations. Q2 revenue growth is guided to approximately 2%, which implies a deceleration from the 'New BDX' growth seen in Q1. This conservatism suggests that management sees risks or timing shifts in the remainder of the year, potentially related to the 10% of the portfolio facing headwinds (China VBP, Vaccines) or the phasing of commercial initiatives, which could limit upside surprises in the near term.
China market dynamics and Volume-Based Procurement (VBP) continue to pressure growth, specifically within the Medical Essentials and specimen management portfolios. Management expects VBP to impact 80% of their portfolio by 2026. While they note positive volume growth, the price compression in these markets creates a persistent structural headwind that requires offsetting growth in other regions or segments, limiting the overall organic growth potential of the base business.
Overall: Management exhibited a confident and disciplined demeanor, emphasizing 'stronger-than-expected results' and the successful execution of their strategic transformation into a pure-play medtech company. While acknowledging headwinds from tariffs and specific product lines like Alaris, executives remained focused on the long-term growth drivers and operational efficiencies of the 'New BDX'.
Confidence: HIGH - Management provided specific metrics regarding share gains (e.g., Alaris +100 bps), commercial execution (Pyxis Pro conversion rates), and capital deployment details. The early closing of the Waters transaction and immediate deployment of capital further underscored their confidence in the company's financial position and strategic direction.
Low single-digit growth (New BDX)
Approximately 25%
$12.35 to $12.65
Approximately 2%
$2.72 to $2.82
Hedging & Uncertainty: Management employed hedging language primarily regarding the duration of specific headwinds and the phasing of the fiscal year. Terms like 'prudent approach,' 'expected to be,' and 'approximately' were used when discussing guidance and the Alaris ramp. For instance, Vitor Roach stated, 'with just one quarter behind us, we are maintaining a prudent approach to our guidance,' which serves to lower expectations for immediate upward revisions despite a strong Q1 beat. Thomas Polen used temporal hedges regarding Alaris, noting it is at the 'tail end' of remediation but that the headwind will 'step up' in 2027, effectively managing investor expectations for a delayed recovery in that specific segment.
We delivered stronger-than-expected results, which reflect our disciplined execution... - Thomas E. Polen, Chairman, Chief Executive Officer, and President
We are maintaining a prudent approach to our guidance for new Becton, Dickinson and Company. - Vitor Roach, Senior Vice President and Interim Chief Financial Officer
We expect Alaris to step up in 2027... 200 basis point headwind... - Thomas E. Polen, Chairman, Chief Executive Officer, and President
We feel really good about our portfolio... We do not expect them to, we expect them to continue strong through the year. - Thomas E. Polen, Chairman, Chief Executive Officer, and President
There's no ramp first half to second half either, right, which is a much better spot... - Thomas E. Polen, Chairman, Chief Executive Officer, and President
Analyst Sentiment: Analysts were largely congratulatory regarding the closing of the Waters transaction and the beat on Q1 expectations. Questions focused heavily on the sustainability of growth in the 'New BDX' portfolio, specifically asking for clarification on the 'mid-single-digit' growth potential and the cadence of the Alaris and vaccine headwinds.
Management Responses: Thomas Polen handled the majority of the questions, providing detailed, metric-backed responses that reinforced confidence in the commercial strategy. He was direct about the 'transitory' nature of current headwinds like Alaris and vaccines, emphasizing the strength of the underlying fundamentals. Vitor Roach provided concise financial clarifications, particularly regarding the Q2 step-down and margin targets.
Discussion on the 'New BDX' growth profile and whether structural changes prevent a return to mid-single-digit growth. Management affirmed the portfolio quality, noting 90% of the business is growing mid-single-digits.
Detailed inquiry into the 10% of the portfolio facing headwinds (Alaris, Vaccines, China). Management clarified that Alaris headwinds will persist into 2027 (200 bps impact) but that they are gaining share.
Questions regarding the Q2 revenue guidance of 2% despite easy comparisons. Management explained this as a timing issue with Biopharma and MMS, normalizing growth between Q1 and Q2.
Inquiries into GLP-1 growth trajectory and oral vs. injectable dynamics. Management remained bullish on injectables, citing $1B potential by decade-end and strong pharma capacity investments.
BDX has successfully navigated a complex portfolio transformation to emerge as a focused, pure-play medtech company ('New BDX'). The closing of the Waters transaction and immediate deployment of $4 billion in cash ($2B buybacks, $2B debt) signals a shareholder-friendly era and financial discipline. While near-term earnings are pressured by tariffs and the Alaris remediation tail (impacting growth by ~200 bps), the core business is demonstrating resilience with 2.5% underlying growth and double-digit expansion in high-margin platforms like GLP-1 delivery and pharmacy automation. The guidance for a 25% operating margin implies significant confidence in operational efficiency ('BD Excellence') to offset inflation. As the company laps the Alaris headwinds in 2027 and commercial investments scale, revenue and EPS growth are poised to re-accelerate, making the current valuation an attractive entry point for long-term investors.
Volume-Based Procurement (VBP) in China continues to compress pricing, impacting Medical Essentials and vaccines. Management expects VBP to affect 80% of their portfolio by 2026, creating a persistent structural price headwind despite volume growth.
Hospital demand trends remain steady, but labor shortages are driving CapEx spending towards automation solutions. BDX's Pharmacy Automation and Pyxis platforms are benefiting as hospitals seek to reduce labor costs and improve workflow efficiency.
Tariffs had a significant 170-basis point impact on gross margins in Q1 and are expected to remain a headwind throughout fiscal 2026, necessitating pricing actions and productivity improvements to maintain margins.